Article Data

  • Views 106
  • Dowloads 1


Open Access

Renal function and icu


1Professor of Anestesia and Intensive Care

2Department of Anesthesia and Intensive Care Azienda Ospedaliero-Universitaria Udine

DOI: 10.22514/SV21.052007.2 Vol.2,Issue S1,May 2007 pp.11-18

Published: 01 May 2007

*Corresponding Author(s): MANUELA LUGANO E-mail:

PDF (80.41 kB)


Introduction: The mortality of acute renal failure (ARF) is 50-80% in critically ill patients and has not fallen significantly despite numerous advances in critical care strategies and renal replacement technologies over several decades. (1) A major problem with conducting research into acute renal failure (ARF) is the lack of a consensus definition (2). More than 30 different definitions of ARF have been used in the literature. This lack of a common reference point created confusion and made comparisons difficult. The Acute Dialysis Initiative (ADQI) group of experts developed and published a consensus definition of ARF. This definition goes under the acronym of RIFLE. This definition classified the patients with renal dysfunction according to the degree of impairment into patient at risk (R), with injury (I), with failure (F), with sustained loss (L) and with end stage (E) status in relation to their renal function. (2) Rifle criteria were based on changes in the patients’ glomerular filtration rate (GFR) and/or their urine output. (2)

Discussion: The prophylactic and therapeutic use of dopamine, the more studied vasoactive drug, actually has not been supported. For all other vasoactive drugs, at this moment, data available are contradictory and few conclusions can be made. To protect renal function, despite wide use of vasoactive drugs, only the maintenance of adequate volume replacement and perfusion pressure may be certainly recommended.

Conclusion: The use of vasoactive drugs is a pervasive practice in intensive care units, and hence, this area needs suitably powered, multi-center, randomized, placebo-controlled, double-blind studies to provide more rational indications for clinical practice.

Key words

intensive care unit, acute renal failure, renal protec-tion, hemodynamic management, vasoactive drugs, renal replacement therapy

Cite And Share

GIORGIO DELLA ROCCA ,MANUELA LUGANO. Renal function and icu. Signa Vitae. 2007. 2(S1);11-18.


1. I. Y. Tang, P.T. Murray. Prevention of perioperative acute renal failure: waths work? Best Pract & Res Clin Anaesth 18(1):91-111;2004.

2. N. Danton, J.P. Viale, P.Y. Gueugniaud, J.J. Lehot, V. Piriou. Perioperative administration of betablockers: a practice survey, Annales francaise d’anesthesie et de reanimation 23:1057-1062; 2004.

3. A. O’Riordan, V. Wong, R. McQuillan, P.A. McCormick, J.E. Hegarty, A. J. Watson. Acute renal disease, as defined by the RIFLE Criteria, post-liver transplantation, Am J Trasplant 7:168-176;2007

4. D. Palumbo, G. Servillo, L. D’Amato, M.L. Volpe, G. Capogrosso, E. De Robertis, O. Piazza, R. Tufano. The effects of hydroxyethyl starch solution in critically ill patients. Min Anest 72(07-08):655;2006

5. R.A. Zager, A.C. Johnson, S. Lund, S. Y. Hanson, C. K. Abrass. Levosimendan protects against experimental endotoxemic acute renal failure, Am J Physiol Renal Physiol 290:1453-1462, 2006.

6. R.W.C. Lee, D. Di Giantomasso, C. May, R. Bellomo. Vasoactive drugs and the kidney, Best Pratcice & Research Clin Anaest, 18(1):53-74, 2004.

7. A.R. Girbes. Prevention of acute renal failure: role of vaso-active drugs, mannitol and diuretics. Int J Artif Organs 27(12):1049-1053, 2004.

8. N. Brienza, V. Malcagni, L. Dalfino, P. Trerotoli, C. Gagliardi, D. Bortone, G. Faconda, M. ribrezzi, G. Ancona, F. Bruno, T. Fiore. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of criticaly ill patients. Crit Care Med 34(3): 707-714, 2006.

9. G. Landoni, G.G. Biondi-Zoccai, J.A. Tumlin, T. Bove, M. De Luca, M. G. Calabro, M. Ranucci, A. Zangrillo. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analisys of randomized clinical trials. Am J kidney Dis 49(1): 56-68;2007.

10. J.A. Kellum, M. Leblac, R.T. Gibney, J. Tumlin, W. Lieberthal, C. Ronco. Primary prevention of acute renal failure in the critically ill. Curr Opin Crit Care 11(6):537-541, 2005.

11. M. Schetz Should we use diuretics in acute renal failure? Best practice & Research Clin Anaesth 18(1):75-89;2004.

12. J. O. Friedrich, N. Adhikari, M. S. Herridge, J. Beyene. Meta-analysis: low-dose dopamine increase urine output but does not prevent renal dysfuction or death. Ann Intern Med 142(7):510-524, 2005.

13. M. Richer, S. Robert, M. Lebel. Renal hemodynamics during norepinephrine and low-dose dopamine infusions in man. Crit Care Med 24(7): 1150-1156, 1996.

14. J.A. Kellum, M. Decker, R.N. Janine. Use of dopamine in acute renal failure: A meta-analysis. Crit Care Med, 29(8):1526-1531, 2001.

15. R.L. Mehta, M.T. Pascual, S. Soroko, G.M. Chertow, PICARD Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. J Am Med Ass, 288:2547-2553, 2002.

16. C. Ichai, C. Passeron, M. Carles. Prolonged low dose dopamine infusion induces a transient improvement in renal function in hemodynamically stable, critically ill patients: a single blind, prospective, controlled study. Crit Care Med, 28:1329-1335, 2000.

17. P.E. Marik, J. Iglesias. Low-dose dopamine does not prevent acute renal failure in patients with septic ahock and oliguria. Am J Med 107:387-390, 1999.

18. M.I. Rudis. Low-dose dopamine in the intensive care unit: DNR or DN (prescription take)? Crit Care Med, 29(8):1538-1539, 2001.

19. RN Juste, L. Moran, J. Hooper. Dopamine clearance in critically ill patients Intensive Care Med, 24 : 1217-1220, 1998.

20. M. Argalious, P. Motta, F. Khandwala, S. Samuel, C. Gorman Koch, A. M. Gillinov, J.P. Yared, N.J. Starr, C.A. Bashour. “Renal dose” dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. Crit Care Med, 33(6):1327-1332, 2005.

21. A. Lauschker, M. Teichgräber, U. Frei, K-U Eckardt. Low-dose dopamine worsen renal perfusion in patients with acute renal failure. Kidney Int, 69:1669-1674, 2006.

22. C. Martin, L. Papazian, G. Perrin, P. Saux, F. Gouin. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest, 95:1226-1231, 1993.

23) R. Bellomo. Nordrenalin: friend or foe? Heart Lung Circ 12 suppl2:S42-48, 2003.

24. M. Albert, M.R. Losser, D. Hayon, V. Faivre, D. Payen. Systemic and renal macro- and microcirculatory responses to arginine vasopressin in endotoxic rabbits, Crit Care Med, 32(9):1891-1898, 2004.

25. CH Kang, WG Kim. The effect of vasopressin on organ blood flow in an endotoxin-induced rabbit shock model, J Invest Surg 19(6): 361-369, 2006.

26. F. Lauzier, B. Levy, P. Lamarre, O. Lesur. Vasopressin or noepinephrine in early hyperdynamic septic shock:a randomized clinical trial. Intensive Care Med, 32:1782-1789, 2006.

27. F. Fabrizi, V. Dixit, P. Martin. Meta-analysis: terlipressin therapy for hepatorenal syndrome. Aliment Pharmacol Ther, 24:935-944, 2006.

28. J. Albanèse, M. Leone, A. Delmas, C. Martin. Terlipressin or norepinephrine in hyperdynamic septic shock: A prospective, randomized study. Crit Care Med 33(9):1897-1902, 2005.

29. A. Morelli, M. Rocco, G. Conti, A. Orecchioni, A. De Gaetano, F. coluzzi, E. Vernaglione, P. Pelaia, P. Pietropaoli. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 30:597-604, 2004.

30. C. Martin, X. Viviand, M. Leone, X. Thirion. Effects of norepinephrine on the outcome of septic shock. Crit Care Med 28:2758-2765, 2000.

31. N.P.J. Day, N.H. Phu, N.T.H. Mai, D.B. Bethell, T.T. Chau, P.P. Loc, L.V. Chuong, D.X. Sinh, T. Solomon, G. Haywood, T.T. Hien, N.J. White. Effects of dopamine and epinephrine infusions on renal hemodynamics in severe malaria and severe sepsis. Crit Care Med 28: 1353-1362, 2000.

32. A.V.V. Prengel, K.H. Lindner, V. Wenzel... Splanchnic and renal blood flow after cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Resuscitation 38:19-24, 1998.

33. D. Tobata, K. Takao, M. Mochizuki, R. Nishimura, N. Sasaki. Effects of dopamine, dobutamine, Amrinone and Milrinone on regional blood in isoflurane anesthetized dogs. J Vet Med Sci 66(9):1097-1105, 2004.

34. L. Huang, M. H. weil, W. Tang, S. Sun, J. Wang. Comparison between dobutamine and levosimendan for management of postresuscitation myocardial dysfunction. Crit Care Med 33(3):487-491, 2005.

35. C. Ertmer, A. Morelli, H.G. Bone, H.D. Stubbe, R. Schepers, H. Van Aken, M. Lange, K. Bröking. M. Lücke, D.L. Traber, M. Westphal. Dobutamine reverse the vasopressin-associated impairment in cardiac index and systemic oxygen supply in ovine endotoxemia, Crit Care 10(5):R144.

36. M.C. Renton, C.P. Snowden. Dopexamine and its role in the protection of  hepatosplanchnic and renal perfusion in high-risk surgical and critically ill patients, Br J Anaesth 94(4):459-467, 2005.

37. C. J. Ralph, S.J. Tanser, p.D. Mac Naughton… A randomised controlled trial investigating the effects of dopexamine on gastrointestinal function and organ dysfunction in the critically ill. Int Care Mes 28:884-890, 2002.

38. R.A. Zager, A. C. Johnson, S. Lund, S. Y: hanson, C. K. Abrass. Levosimendan protects against experimental endotoxemic acute renal failure, Am J physiol renal Physiol 290:1453-1462;2006.

39. A. Oldner, D. Konrad, E. Weitzberg, A. Ruclehill, P. Rossi, M. Wanecek. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med, 29:2185-2193, 2001.

40. J. Abrams. Hemodynamic effects of nitrolgiceryn and long-acting nitrates. Am Heart J, 110(1 Pt2):216-224, 1985.

41. U. Elkayam, G. Cohen, H. Gogia, A. Mehra, J. V. Johnson, P. A. N. Chandraratna. Renal vasodilatory effect of endothelial stimulation in patients with chronic congestive heart failure. JACC 28(1):176-182, 1996.

42. M. Petersson, P. Friberg, G. Lambert, B. Rundqvist. Decrease renal sympathetic activity in response to cardiac anloading with nitroglycerin in patients with heart failure. Eur J Heart Fail. 7(6):1003-1010, 2005.

43. C. Mandragos, C. Sarantopoulos, A. Amygdalou, P. K. Behrakis. Prolonged high-dose administration of sodium nitroprusside in the intensive care unit. Intensive Care Med.24(8):889, 1998.

44. M. Halpenny, C. Rushe, P. Breen, A.J. Cunningham, D. Boucher-Hayes, G.D. Shorten. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery, Eur J Anesthesiol 19:32-39, 2002.

45. I. Fontana, M.R. Germi, M. Beatini, S. Fontana, M. Bertocchi, E. Porcile, L. Saltalamacchia, S. Ornis, D. Ghinolfi, L. Bonifacio, U. Valente. Dopamine “renal dose” versus fenoldopam mesylate to prevent ischemia-reperfusion injury in renal transplantation. Transplantation Proceedings, 37: 2474-2475, 2005.

46. G. Della Rocca, L. Pompei, M.G. Costa, C. Coccia, L. Scudeller, P. Di Marco, S. Monaco, P. Pietropaoli. Fenoldopam mesylate and renal function in patients undergoing liver transplantation: a randomized, controlled pilot trial. Anesth Analg, 99:160401609, 2004.

47. G. Biancofiore, G. Della Rocca, L. Bindi, A. Romanelli, M. Esposito, L. Meacci, L. Urbani, F. Filipponi, F. Mosca. Use of fenoldopam to control reanl dysfunction early after liver transplantation. Liver Transpl, 10: 986-992, 2004.

48. S. D. Weisbord, P. M. Palevsky. Radiocontrast-induced acute renal failure, J Intensive Care Med 20:63-75;2005.

49. R. Vanholder, W. Van Biesen, N. Lameire. What is the renal replacement method of first choice for intensive care patients?, J Am Soc Nephrol 12:S40-S43;2001

50. R. Bellomo, C. Ronco. Indication and criteria for initiating renal replacement therapy inthe intensive care unit. Kidney Int Suppl 66:S106-109;1998

51. C. Ronco, C. Tetta, F. Mariano, M.L. Wratten, M. Bonello, V. Bordoni, X. Cardona, P. Ingaggiato, L. Pilotto, V. D’Intini, R. Bellomo. Interpretino the mechanism of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 27(9):792-801;2003

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) The Science Citation Index (SCI) is a citation index originally produced by the Institute for Scientific Information (ISI) and created by Eugene Garfield. It (Science Citation Index Expanded) covers more than 8,500 notable and significant journals, across 150 disciplines in science and technology, from 1900 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time